Primary Recipient

SEQUELLA INC

Amount

$693,529.00

Award Date

9/22/2009

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

Investigation of Synergy between Rifampin (RIF) and SQ109, a New Anti-TB Drug Candidate. Purpose is to replenish the SQ109 API so that we can complete the Specific Aims of the R21 grant, to have enough API to complete the investigation of SQ109 and RIF sy